Aprotinin aerosol reduces hospital stay in COVID-19 patients

Published On 2022-04-13 03:30 GMT | Update On 2022-12-14 11:47 GMT

FRANKFURT: SARS-CoV-2, the coronavirus that causes COVID-19, needs its spike proteins to dock onto proteins (ACE receptors) on the surface of the host cells. Before this docking is possible, parts of the spike protein have to be cleaved by host cell's enzymes called proteases. In 2020, a scientific team led by Professor Jindrich Cinatl (Goethe University Frankfurt, Germany), Professor Martin Michaelis and Professor Mark Wass (both University of Kent, UK), conducted cell culture experiments and found that aprotinin, a protease inhibitor, could inhibit virus replications by preventing SARS-CoV-2 entry into host cells.

In a more recent study, the research consortium further showed that aprotinin is also effective against the Delta and Omicron variants.

Now, a Spanish research consortium has published the findings of a phase III clinical study investigating the use of an aprotinin aerosol in COVID-19 patients. Among other improvements, aprotinin treatment reduced the length of hospital stays by five days.

Professor Jindrich Cinatl, Goethe University Frankfurt, said: "This shows how scientific collaborations work even without a direct relationship between researchers. I am very glad that our cell culture study inspired this successful clinical trial".

Professor Martin Michaelis, University of Kent, said: "Our cell culture data looked very convincing. It is exciting that aprotinin has now also been shown to be effective against COVID-19 in patients."

To read the full article, click on this link:

10.1111/eci.13776

Article Source : European Journal of Clinical Investigation

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Aprotinin aerosol reduces hospital stay in COVID-19 patients

Similar News

Sex Influences Quality-of-Life Outcomes in Peanut Oral Immunotherapy: Study

Hidradenitis Suppurativa Linked to Higher Risk of Serious Eye Diseases: Study

Rising Burden of Asthma and COPD Among Older Indians Linked to Social and Household Factors, Finds Study

Hypoglycaemia Awareness Key to Predicting Severe Events in Type 1 Diabetes, Study Shows

Digitoxin Reduces Mortality and Hospitalizations in Heart Failure with Reduced Ejection Fraction: NEJM

HEPA Filters Lower Blood Pressure in High-Pollution Areas: Study

Age-related Eye Diseases Increase Risk of Comorbid CHD and Depression, reveals study

Vancomycin Linked to Higher AKI Risk in ICU Patients: Study